Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÇÙ»êÁõÆø°Ë»ç ÆÇÁ¤ºÒ´É °á°ú¸¦ º¸ÀÎ ÇåÇ÷ Ç÷¾×¿¡¼­ HCV ¶Ç´Â HIV Ç¥ÁöÀÚ ¿¬°ü¼º Á¶»ç Investigation of the Association of HCV or HIV Markers in Non-Discriminated Blood Donations

´ëÇѼöÇ÷ÇÐȸÁö 2019³â 30±Ç 2È£ p.163 ~ 167
°­Á¤¿ø, ½Å¼±¹Ì, °­Àç¿ø, ¼­¿µÀÍ, ¹ÎÇõ±â, ±è¸íÇÑ,
¼Ò¼Ó »ó¼¼Á¤º¸
°­Á¤¿ø ( Kang Jung-Won ) 
´ëÇÑÀû½ÊÀÚ»ç Ç÷¾×¼öÇ÷¿¬±¸¿ø

½Å¼±¹Ì ( Shin Sun-Mi ) 
´ëÇÑÀû½ÊÀÚ»ç Áß¾ÓÇ÷¾×°Ë»ç¼¾ÅÍ
°­Àç¿ø ( Kang Jae-Won ) 
´ëÇÑÀû½ÊÀÚ»ç Ç÷¾×¼öÇ÷¿¬±¸¿ø
¼­¿µÀÍ ( Seo Young-Ik ) 
´ëÇÑÀû½ÊÀÚ»ç Ç÷¾×¼öÇ÷¿¬±¸¿ø
¹ÎÇõ±â ( Min Hyuk-Ki ) 
´ëÇÑÀû½ÊÀÚ»ç Ç÷¾×¼öÇ÷¿¬±¸¿ø
±è¸íÇÑ ( Kim Myung-han ) 
´ëÇÑÀû½ÊÀÚ»ç Ç÷¾×°ü¸®º»ºÎ

Abstract


HBV core antibody and surface antibody test are currently conducted for those donors showing non-discriminated reactive (NDR) results on a nucleic acid amplification test (NAT) as a blood donor screening assay. It is necessary to investigate the relationship with HCV or HIV in the donors showing NDR results. From June 12th, 2012 to December 31st, 2018, 0.05% (9,020/17,798,461) donors showed NDR results on a NAT. Among the donors showing NDR results, 17 and 18 donors showed positive results on serological assay of HCV and HIV, respectively. 23 donors with NDR results showed positive results on the serological assay or NAT for HCV or HIV on the following donation. Further study and more accumulated data are required because it may be difficult to find the cause of NDR results by the current serological assay that is used for screening blood donors.

Å°¿öµå

Non-discriminated reactive; Nucleic acid amplification test; HCV; HIV

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS